07.21.14
Headquarters: New York City
twitter.com@pfizer_news
www.pfizer.com
TOP SELLING DRUGS
Pfizer is often portrayed as a corporate predator, even on pharma industry blogs, which have chronicled the company’s acquisition of Warner-Lambert, Pharmacia, and Wyeth. “The only way for a shark to survive is to keep going forward,” wrote John Lamattina in his blog on Forbes.com in May. “To maintain its leadership, Pfizer will again need to make a major acquisition in the next four to five years.” Lamattina, an alumnus of Pfizer, spent several years as head of the corporation’s R&D.
By the end of May, the company decided to bail on its $120-billion bid for AstraZeneca, which would have formed the largest pharma company in the world.
Looking within, Pfizer has shaken off divisions, such as its animal health products, which was spun off as Zoetis last year, to invest in R&D in areas such as oncology immunotherapies.
On the other extreme, however, it is also taking advantage of the trend of brand-name pharmaceuticals to OTC formulations, acquiring Nexium rights from AstraZeneca two years ago. This quarter, the FDA approved OTC Nexium 24HR.
This summer, Pfizer opened a new 280,000 sq.-ft. R&D hub in Cambridge, MA, which will allow 1,000 scientists from three
locations to work in one spot, closer to academic institutions, hospitals and patient organizations, on treatments for lupus,
inflammatory bowel disease, kidney disease, Type 2 diabetes, muscular dystrophy and Parkinson’s disease.
This year, Pfizer plans to submit a NDA with the FDA for palbociclib combined with letrozole, as first-line treatment of estrogen receptor positive (ER+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
Pfizer is also working with Merck, exploring the therapeutic potential of Merck’s anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. A Phase I/II study will evaluate MK-3475 with axitinib (INLYTA) in renal cell carcinoma, and a Phase I study will evaluate MK-3475 and PF-2566, a fully humanized mAb involved in regulation of immune cell proliferation and survival.
Last year, FDA approved Xalkori for the treatment of patients with metastatic non-small cell lung cancer.
twitter.com@pfizer_news
www.pfizer.com
Headcount: | 77,700 | |
Year Established: | 2000 | |
Pharma Reveneus: | $51,220 | -6% |
Total Revenues: | $51,584 | -6% |
Net Income: | $22,072 | 51% |
R&D Budget: | $6,678 | -11% |
TOP SELLING DRUGS
Drug | Indication | 2013 sales | (+/- %) |
Lyrica | epilepsy, neuralgia and neuropathy | $4,595 | 11% |
Prevnar | vaccine pneumococcal disease | $3,974 | -3% |
Enbrel | rheumatoid, juvenile arthritis | $3,774 | 1% |
Celebrex | arthritis pain and inflammation | $2,918 | 7% |
Lipitor | reducation of LDL cholesterol | $2,315 | -41% |
Viagra | erectile dysfunction | $1,881 | -8% |
Zyvox | bacterial infections | $1,353 | 1% |
Norvasc | hypertension | $1,229 | -9% |
Sutent | renal cell carcinoma | $1,204 | -3% |
Premarin | menopause | $1,092 | 2% |
BeneFIX | hemophilia | $832 | 7% |
Vfend | fungal infections | $775 | 3% |
Genotropin | replacement of human growth hormone | $772 | -7% |
Pristiq | depression | $698 | 11% |
Chantix | addiction to smoking | $648 | -3% |
Pfizer is often portrayed as a corporate predator, even on pharma industry blogs, which have chronicled the company’s acquisition of Warner-Lambert, Pharmacia, and Wyeth. “The only way for a shark to survive is to keep going forward,” wrote John Lamattina in his blog on Forbes.com in May. “To maintain its leadership, Pfizer will again need to make a major acquisition in the next four to five years.” Lamattina, an alumnus of Pfizer, spent several years as head of the corporation’s R&D.
By the end of May, the company decided to bail on its $120-billion bid for AstraZeneca, which would have formed the largest pharma company in the world.
Looking within, Pfizer has shaken off divisions, such as its animal health products, which was spun off as Zoetis last year, to invest in R&D in areas such as oncology immunotherapies.
On the other extreme, however, it is also taking advantage of the trend of brand-name pharmaceuticals to OTC formulations, acquiring Nexium rights from AstraZeneca two years ago. This quarter, the FDA approved OTC Nexium 24HR.
This summer, Pfizer opened a new 280,000 sq.-ft. R&D hub in Cambridge, MA, which will allow 1,000 scientists from three
locations to work in one spot, closer to academic institutions, hospitals and patient organizations, on treatments for lupus,
inflammatory bowel disease, kidney disease, Type 2 diabetes, muscular dystrophy and Parkinson’s disease.
This year, Pfizer plans to submit a NDA with the FDA for palbociclib combined with letrozole, as first-line treatment of estrogen receptor positive (ER+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
Pfizer is also working with Merck, exploring the therapeutic potential of Merck’s anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. A Phase I/II study will evaluate MK-3475 with axitinib (INLYTA) in renal cell carcinoma, and a Phase I study will evaluate MK-3475 and PF-2566, a fully humanized mAb involved in regulation of immune cell proliferation and survival.
Last year, FDA approved Xalkori for the treatment of patients with metastatic non-small cell lung cancer.